Background: Atherosclerotic renal artery stenosis (ARAS) is an important cause of renal disease in the elderly, and these patients have a high morbidity and mortality. There are no data on their blood lipid profiles. Methods: The lipoprotein profiles were examined in patients with proven ARAS and compared with patients matched for age, gender, renal function and presence of diabetes. Results: The profiles did not show any significant difference for apolipoprotein B (control 1.31 ± 0.39 vs. ARAS 1.24 ± 0.28; mean ± SD), cholesterol (control 5.65 ± 1.28 vs. ARAS 6.12 ± 1.29), LDL cholesterol (control 3.72 ± 1.03 vs. ARAS 4.06 ± 1.18), fibrinogen (control 2.48 ± 1.39 vs. ARAS 3.29 ± 1.49), HDL cholesterol (control 1.16 ± 0.38 vs. ARAS 1.00 ± 0.26) and triglyceride (control 1.68 ± 0.80 vs. ARAS 2.32 ± 1.73) levels between the groups. Surprisingly lipoprotein(a) levels were higher in the control group (0.58 ± 0.45) vs. ARAS (0.31 ± 0.21). The most striking abnormality was the markedly lower apolipoprotein A1 levels in the ARAS group (control 2.09 ± 0.55 vs. ARAS 0.95 ± 0.30) and apolipoprotein A1/B ratio (control 1.74 ± 0.71 vs. ARAS 0.78 ± 0.24). Conclusion: The lipoprotein abnormality in ARAS mirrors that in other severe vascular diseases. Potential therapeutic interventions in patients with ARAS should consider treatments to modify the apolipoprotein A1 concentration rather than cholesterol alone.

Keywords:
Renal artery stenosis, Apolipoprotein A1, Cholesterol, High-density lipoprotein, Low-density lipoprotein
1.
Kalra PA, Mamtora H, Holmes AM, Waldek S: Renovascular disease and renal complications of angiotensin-converting enzyme inhibitor therapy. Q J Med 1990;77:1013–1018.
2.
Scoble JE, Maher ER, Hamilton G, Dick R, Sweny P, Moorhead JF: Atherosclerotic renovascular disease causing renal impairment: A case for treatment. Clin Nephrol 1989;31:119–122.
3.
Pickering TG, Herman L, Devereux RB, Sotelo JE, James GD, Sos TA, et al: Recurrent pulmonary oedema in hypertension due to bilateral renal artery stenosis: Treatment by angioplasty or surgical intervention. Lancet 1988;ii:551–552.
4.
Mailloux LU, Belluci AG, Napolitano B, Mossey T, Wilkes BM, Bluestone PA: Survival estimates for 683 patients starting dialysis from 1970 through 1989: Identification of risk factors for survival. Clin Nephrol 1994;42:127–135.
5.
Harding MB, Smith LR, Himmelstein SI, Harrison JK, Phillips HR, Schwab SJ, et al: Renal artery stenosis: Prevalence and associated risk factors in patients undergoing routine cardiac catheterization. J Am Soc Nephrol 1992;2:1608–1616.
6.
Swartbol P: Renal artery stenosis in patients with peripheral vascular disease and its correlation to hypertension. A retrospective study. Int Angiol 1992;11:195–199.
7.
Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group: Natural history of aortic and coronary atherosclerotic lesions in youth. Findings from the PDAY Study. Arterioscler Thromb 1993;13:1291–1298.
8.
Zierler RE, Bergelin RO, Isaacson JA, Strandness DE: Natural history of atherosclerotic renal artery stenosis: A prospective study with duplex ultrasonography. J Vasc Surg 1994;19:250–258.
9.
Guzman RP, Zierler RE, Isaacson JA, Bergelin RO, Strandness DE: Renal atrophy and arterial stenosis: A prospective study with duplex ultrasound. Hypertension 1994;23:346–350.
10.
Novick AC: Patient selection for intervention to preserve renal function in ischemic renal disease; in Novick A, Scoble J, Hamilton G (eds): Renal Vascular Disease. London, Saunders, 1995, pp 323–335.
11.
Ross R: The pathogenesis of atherosclerosis: A perspective for the 1990s. Nature 1993;362:801–809.
12.
Vidt DG, Eisele G, Gephardt GN, Tubbs R, Novick AC: Atheroembolic renal disease: Association with renal artery stenosis. Cleveland Clin J Med 1989;56:407–413.
13.
Woolfson RG, Lachmann H: Improvement in renal cholesterol emboli syndrome after simvastatin. Lancet 1998;351:1331–1332.
14.
Friedewald WT, Levy RI, Fredrickson DS: Estimation of the concentration of low-density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem 1972;18:499–502.
15.
Watts GF, Mazurkiewicz JC, Tonge K, Nelson V, Warburton FG, Slavin BM: Lipoprotein(a) as a determinant of the severity of angiographically defined carotid atherosclerosis. Q J Med 1995;88:321–326.
16.
Effect of simvastatin on coronary atheroma: The multicentre anti-atheroma study. Lancet 1994;344:633–638.
17.
Kronenberg F, Utermann G, Dieplinger H: Lipoprotein(a) in renal disease. Am J Kidney Dis 1996;27:1–25.
18.
Black IW, Wilkden DEL: Decreases in apolipoprotein(a) after renal transplantation: Implications for lipoprotein(a) metabolism. Clin Chem 1992;38:353–357.
19.
Missouris CG, Barley J, Jeffery S, Carter ND, Singer DRJ, MacGregor GA: Genetic risk for renal artery stenosis: Association with deletion polymorphism in angiotensin 1-converting enzyme gene. Kidney Int 1996;49:534–537.
20.
Randomised trial of cholesterol lowering in 4,444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (45). Lancet 1994;344:1383–1389.
21.
Contois JH, McNamara JR, Lammi-Keefe CJ, Wilson PWF, Massov T, Schaefer EJ: Reference intervals for plasma apolipoprotein A1 determined with a standardized commercial immunoturbidimetric assay: Results from the Framingham Offspring Study. Clin Chem 1996;42:507–514.
1999
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.